{"id":12713,"date":"2009-01-23T10:30:00","date_gmt":"2009-01-23T09:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/aboutpharma-rassegna-stampa-dal-200109-al-220109\/"},"modified":"2009-01-23T10:30:00","modified_gmt":"2009-01-23T09:30:00","slug":"aboutpharma-rassegna-stampa-dal-200109-al-220109","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/aboutpharma-rassegna-stampa-dal-200109-al-220109\/","title":{"rendered":"ABOUTPHARMA, Press Review from 20\/01\/09 to 22\/01\/09"},"content":{"rendered":"<p><strong><strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\">Press Review from<\/span><\/font><\/strong><\/strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\"> <strong><strong><font face=\"Arial\"><span style=\"font-family: Arial\">20\/01\/09<\/span><\/font><\/strong><\/strong><\/span><\/font><strong><strong><font face=\"Times New Roman\" color=\"#ff0000\"><span style=\"color: red\">&nbsp;<\/span><\/font><\/strong><\/strong><strong><strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\">to the<\/span><\/font><font color=\"#ff0000\"><span style=\"color: red\">&nbsp;<\/span><\/font><\/strong><\/strong><strong><strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\">22\/01\/09<\/span><\/font><\/strong><\/strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\">&nbsp;<\/span><\/font><\/p>\n<p><strong><font face=\"Arial\" color=\"#000080\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: navy; font-family: Arial\">&nbsp;<\/span><\/font><\/strong><\/p>\n<p><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">In 2008, Abbott earned $5 billion<\/span><\/font><\/strong><\/p>\n<p><font face=\"Arial\" size=\"2\"><span lang=\"EN-GB\" style=\"font-size: 10pt; font-family: Arial\">(International Herald Tribune: p. 13, The Wall Street Journal online, Les Echos online - January 22, 2009)<\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">Abbott closed 2008 on a positive note: net income increased by 35% to $4.8 billion and turnover increased by 13.9% to $29.5 billion. In the 4th quarter, net income increased 28%, driven primarily by sales of arthritis drug Humira (adalimumab). For 2009, Abbott estimates earnings per share of between $3.35 and $3.70.<\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><a target=\"_blank\" href=\"http:\/\/www.aboutpharma.it\/notizia.asp?id=18682\" rel=\"noopener\">http:\/\/www.aboutpharma.it\/<wbr><\/wbr>news.asp?id=18682<\/a><\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">&nbsp;<\/span><\/font><\/p>\n<p><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">EU: Roche&#039;s drug for rheumatoid arthritis approved<\/span><\/font><\/strong><\/p>\n<p><font face=\"Arial\" size=\"2\"><span lang=\"EN-GB\" style=\"font-size: 10pt; font-family: Arial\">(The Wall Street Journal online - January 22, 2009)<\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">The European Union has approved the marketing of RoActemra (tocilizumab), a drug for the treatment of rheumatoid arthritis co-developed by Roche and its Japanese subsidiary Chugai. The medicine will be combined with another drug in adult patients who are unresponsive or intolerant to other therapies.<\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><a target=\"_blank\" href=\"http:\/\/www.aboutpharma.it\/notizia.asp?id=18681\" rel=\"noopener\">http:\/\/www.aboutpharma.it\/<wbr><\/wbr>news.asp?id=18681<\/a><\/span><\/font><\/p>\n<p><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">&nbsp;<\/span><\/font><\/p>\n<p><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">US: 635 million dollars to eradicate polio<\/span><\/font><\/strong><\/p>\n<p><font face=\"Arial\" size=\"2\"><span lang=\"EN-GB\" style=\"font-size: 10pt; font-family: Arial\">(The Wall Street Journal<\/p>","protected":false},"excerpt":{"rendered":"<p>Rassegna Stampa dal 20\/01\/09&nbsp;al&nbsp;22\/01\/09&nbsp; &nbsp; Nel 2008 Abbott ha guadagnato 5 mld di dollari (International Herald Tribune: pag. 13, The Wall Street Journal online, Les Echos online &#8211; 22 gennaio 2009) Abbott ha concluso positivamente il 2008: l&#8217;utile netto &egrave; aumentato del 35% raggiungendo i 4,8 mld di dollari ed il giro d&#8217;affari &egrave; cresciuto &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-12713","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=12713"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12713\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=12713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=12713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=12713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}